Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

AbbVie vows to keep drug price increases below 10 percent

AbbVie Inc Chief Executive Richard Gonzalez on Wednesday promised to keep all drug price increases in 2017 under 10 percent, becoming the third global drugmaker to publicly make that pledge.

Speaking at the annual JP Morgan Healthcare Conference in San Francisco, Gonzalez said his company would raise prices just once this year, and the percentage increases would not exceed single digits.

AbbVie, whose rheumatoid arthritis treatment Humira is the world's biggest-selling drug, joins Allergan and Danish diabetes company Novo Nordisk as the first major drugmakers promising such a limit on price increases.

"There's a strong debate going on right now about pricing," Gonzalez told investors. "We need to make sure we are operating in an appropriate way ... and demonstrating the value of the products that we have."

Drugmakers have come under intense criticism for setting extremely high U.S. prices for new medicines, and for their practice of regularly increasing those prices, often twice a year and by double-digits.

While Gonzalez was making his presentation the pricing debate heated up considerably, as U.S. President-elect Donald Trump attacked the pharmaceutical industry during a news conference.

Trump said drugmakers were "getting away with murder" and promised to start a bidding process over drug pricing that would save the country billions of dollars.

It appeared to be a renewal of a campaign promise Trump made to allow the massive U.S. Medicare health insurance program for the elderly to negotiate drug pricing, something it is currently prohibited by law from doing. Trump's comments sent shares of pharmaceutical and biotech companies lower.

Shares of AbbVie were down 4.0 percent at $60.91 in afternoon trading.

Prior to Trump's news conference, several top pharmaceutical executives at the JP Morgan conference expressed optimism over a Trump administration they see as likely to lower corporate tax rates and allow repatriation of cash held overseas without incurring major penalties.

"I've never been more hopeful than I am now," Gonzalez said, while apparently unaware of Trump's comments at the time.

Even with only single-digit price increases, Gonzalez said he expects global sales of Humira to exceed $18 billion by 2020. Humira had sales in 2015 of about $14 billion.

Gonzalez said there remains room for considerable growth in rheumatoid arthritis and even more in psoriasis.

"The dermatology space has lot of opportunity to continue to drive long-term growth," he said. "It's a very attractive market longer term."

(Reporting by Bill Berkrot; Editing by Leslie Adler)

Wed Jan 11, 2017

Source: http://www.reuters.com/

0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies